218 related articles for article (PubMed ID: 36248989)
1. The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study.
Guo Z; Zhu H; Zhang X; Huang L; Wang X; Shi H; Yu L; Qiu Y; Tu F
Front Oncol; 2022; 12():941068. PubMed ID: 36248989
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
3. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
5. A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST.
Cao G; Zhu X; Li J; Shen L; Yang R; Chen H; Wang X; Gao S; Xu H; Zhu L; Liu P; Guo J
Chin J Cancer Res; 2014 Feb; 26(1):124-31. PubMed ID: 24653635
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients.
Duan XH; Ju SG; Han XW; Ren JZ; Li FY; Chen PF; Wu YY; Li H
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1468-1480. PubMed ID: 32096197
[TBL] [Abstract][Full Text] [Related]
8. Comparison of chemoembolization with CalliSpheres
Liang B; Xiang H; Ma C; Xiong B; Ma Y; Zhao C; Yao Y; Zhang Z; Chen C; Li H; Long Q; Zhou J; Luo C; Qiu H; Hu H; Zhao H; Zhou G; Zheng C
Cancer Manag Res; 2020; 12():941-956. PubMed ID: 32104076
[TBL] [Abstract][Full Text] [Related]
9. Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score.
Zhu ZY; Yuan M; Yang PP; Xie B; Wei JZ; Qin ZQ; Qian Z; Wang ZY; Fan LF; Qian JY; Tan YL
World J Surg Oncol; 2022 Jun; 20(1):192. PubMed ID: 35689233
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study.
Morishita A; Tani J; Nomura T; Takuma K; Nakahara M; Oura K; Tadokoro T; Fujita K; Shi T; Yamana H; Matsui T; Takata T; Sanomura T; Nishiyama Y; Himoto T; Tomonari T; Moriya A; Senoo T; Takaguchi K; Masaki T
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572832
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Li X; Ding X; Li W; Chen J
Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.
Yao M; Cheng S; Zhai X; Zhao H; Hong J; Li X; Meng Y; Chen W
Appl Bionics Biomech; 2022; 2022():9084852. PubMed ID: 36091626
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
16. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.
Gao Y; Lu H; Xiong Z
Front Oncol; 2023; 13():1231359. PubMed ID: 38074659
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
20. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
